VIR BIOTECHNOLOGY INC

VIRNASDAQ

🏆 #2084 by market capEarnings Nov 4US Equity

$193.07▲ $5.95 (+3.08%)

Simulated price

🔔

Track VIR

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 3.1%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$1.77B

Small Cap

📈Revenue Growth (YoY)

-7.6%

Declining

📊Gross Margin

170.0%

High

💵FCF Margin

-109.3%

Thin

⚖️P/S Ratio

5.8x

Fair

Otter Score

Fair

No chart data available for VIR.

Trading Snapshot

Day Range: $190.52 – $196.92
52-Week Range: $4.82 – $11.94
Volume: $1.59B
Avg Volume: $1.10B
Shares Outstanding: 168.7M
Next Earnings: Nov 6, 2026

Fundamentals Snapshot

Annual Revenue: $69M
Last Q Revenue: $239M
P/E Ratio: -5.7
P/S Ratio: 5.8x
EPS (TTM): $-1.50
Dividend Yield: 0.00%
Dilution (1yr): +1.8%

Why Investors Own VIR

✓High-growth profile — revenue up +48.1% YoY with expanding US Equity exposure.
✓Healthy economics — 41% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

VIR BIOTECHNOLOGY INC

VIR

Financial Trends

Revenue

$69M▼ −7.6% YoY

Gross Margin

82.9%▼ −115.2% YoY

Operating Income

−$468M▼ −20.3% YoY

Free Cash Flow

−$397M▼ −12.6% YoY

Shares Outstanding

139.2M▲ +1.8% YoY

Net Cash

$47M▼ −$78M YoY

StockOtter · stockotter.space

About VIR BIOTECHNOLOGY INC

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.

🦦